KR940013538A - 자기공명 조영 강화제인 수불용성 망간입자 - Google Patents

자기공명 조영 강화제인 수불용성 망간입자 Download PDF

Info

Publication number
KR940013538A
KR940013538A KR1019930022435A KR930022435A KR940013538A KR 940013538 A KR940013538 A KR 940013538A KR 1019930022435 A KR1019930022435 A KR 1019930022435A KR 930022435 A KR930022435 A KR 930022435A KR 940013538 A KR940013538 A KR 940013538A
Authority
KR
South Korea
Prior art keywords
manganese
composition
particles
insoluble
salt
Prior art date
Application number
KR1019930022435A
Other languages
English (en)
Inventor
이. 켈러 케네쓰
에이치. 카핀스키 피터
리버시지 얼라인
에이치. 에이치. 건터 울프갱
엘. 매킨타이어 그레고리
밴 오어먼 바바라
Original Assignee
폴 이. 듀퐁
스터얼링 윈드롭 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 이. 듀퐁, 스터얼링 윈드롭 아이엔씨. filed Critical 폴 이. 듀퐁
Publication of KR940013538A publication Critical patent/KR940013538A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

본원은 거의 수불용성 망간 화합물 입자들로 구성되는 미토콘드리아가 풍부한 기관의 이미징용 자기공명 이미징 조성물에 관한다. 바람직한 구체예에서, 미토콘드리아가 풍부한 기관은 간장이다. 더 바람직한 구체예에서, 입자들은 거의 비자성이다. 다른 바람직한 구체예에서, 입자들의 입도는 약 10마이크론 이하이다.
보다 더 바람직한 구체예에서, 수불용성 망간 화합물은 망간 염이다. 망간 화합물은 바람직하게는 망간 포스페이트, 망간 카보네이트 및 망간 8-하이드록시 퀴놀레이트로 구성되는 그룹에서 선택된다.
다른 바람직한 구체예에서, 본원 조성물은 또 계면활성제를 포함한다.
본원은 또 상기의 수불용성 망간 화합물을 형성하기에 충분한 조건하에 일정시간 동안 망간 원(바람직하게는 망간(ll) 원)을 카운터이온원과 접촉시키는 것으로 구성되는, 거의 수불용성 망간 화합물 입자로 구성되는 미토콘드리아가 풍부한 기관이미징에 유용한 자기공명 이미징 조성물 제조방법에 관한다 바람직한 구체예에서, 접촉은 수용액내에서의 동시 혼합에 의한다.
더 바람직한 구체예에서, 망간원은 가용성 망간염의 수용액이다. 가용성 망간염은 바람직하게는 망간 클로라이드, 망간 니트레이트, 및 망간 설페이트로 이루어지는 그룹에서 선택된다.
본원은 또한 생리적으로 용인할만한 담체내에 현탁 또는 분산된 거의 수불용성 망간 화합물 입자를 조영유효량 포유동물에 투여하여 그 포유동물의 NMR 이미지를 얻는 것으로 구성되는 진단방법에 관한다.

Description

자기공명 조영 강화제인 수불용성 망간입자
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1 도는 본원의 수불용성 망간입자들 주입후 시간에 따른 조직의 이완율 변화를 나타낸다,
제 2 도는 본원의 수불용성 망간입자들 주입후 시간에 따른 조직의 이완율 변화를 나타낸다,
제 3 도는 본원의 수불용성 망간입자들의 여러가지 투약체를 시험 포유동물들의 미정맥(tail veins)에 주입시킨 다음의 간 이완 속도에대한 계면활성제·피복물들의 효과를 나타낸다.

Claims (20)

  1. 거의 불용성인 망간 화합물의 입자들로 구성되는, 미토콘드리아가 풍부한 기관의 이미징용 자기공명 이미징 조성물.
  2. 제 1 항에 있어서, 미토콘드리아가 풍부한 기관이 간장, 신장, 췌장 또는 담관망인 조성물.
  3. 제 1 항에 있어서, 입자들이 거의 비자성인 조성물.
  4. 제 1 항에 있어서, 입자들의 입도가 약 10마이크론 이하인 조성물.
  5. 제 1 항에 있어서, 입자들의 입도가 약 5마이크론 이하인 조성물.
  6. 제 1 항에 있어서, 불용성 망간 화합물이 망간염인 조성물.
  7. 제 1 항에 있어서, 불용성 망간 화합물이 망간 킬레이트인 조성물.
  8. 제 1 항에 있어서, 망간 화합물이 망간 포스페이트, 망간 카보네이트 및 망간 8-하이드록시 퀴놀레이트로 이루어진 그룹에서 선택된 조성물.
  9. 제 1 항에 있어서, 추가로 계면활성제를 포함한 조성물.
  10. 제 9 항에 있어서. 계면활성제가 디미리스토일포스파티딜글리세롤인 조성물.
  11. 불용성 망간 화합물이 형성되기에 충분한 조건하에 일정시간 망간 원(source)을 카운터이온 원과 접촉시키는 것으로 구성되는, 거의 불용성 망간 화합물 입자들로 구성되는 미토콘드리아가 풍부한 기관의 이미징에 유용한 자기공명 이미징 조성물을 제조하는 방법.
  12. 제11항에 있어서, 접촉이 수용액내에서의 동시 혼합에 의한 방법.
  13. 제12항에 있어서, 망간 원이 가용성 망간(II)염의 수용액인 방법.
  14. 제13항에 있어서, 가용성 망간 염이 망간 클로라이드, 망간 니트레이트, 망간 설페이트, 망간 아세테이트 및 망간 플루오라이드로 이루어진 그룹에서 선택된 방법.
  15. 제11항에 있어서, 카운터이온 원이 카보네이트 염의 수용액인 방법.
  16. 제15항에 있어서, 카보네이트 염이 소듐 카보네이트, 포타슘 카보네이트, 및 암모늄 카보네이트로 이루어진 그룹에서 선택된 방법.
  17. 제11항에 있어서, 카운터이온 원이 포스페이트 염의 수용액인 방법.
  18. 제17항에 있어서, 포스페이트 염이 소듐 포스페이트, 포타슘 포스페이트, 및 암모늄 포스페이트로 이루어진 그룹에서 선택된 방법.
  19. 제11항에 있어서, 카운터이온 원이 8-퀴놀리놀의 수용액인 방법.
  20. 생리학적으로 용인할만한 담체내에 현탁 또는 분산된 제 1항의 입자들을 조영 유효량 포유동물에 투여하여 그 동물의 NMR 이미지를 얻는 것으로 구성되는 진단 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930022435A 1992-12-17 1993-10-27 자기공명 조영 강화제인 수불용성 망간입자 KR940013538A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/991,893 US5401492A (en) 1992-12-17 1992-12-17 Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US92/991,893 1992-12-17

Publications (1)

Publication Number Publication Date
KR940013538A true KR940013538A (ko) 1994-07-15

Family

ID=25537695

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930022435A KR940013538A (ko) 1992-12-17 1993-10-27 자기공명 조영 강화제인 수불용성 망간입자

Country Status (15)

Country Link
US (1) US5401492A (ko)
EP (1) EP0605908A3 (ko)
JP (1) JPH06199703A (ko)
KR (1) KR940013538A (ko)
CN (1) CN1102348A (ko)
AU (1) AU4885093A (ko)
CA (1) CA2107695A1 (ko)
CZ (1) CZ265093A3 (ko)
FI (1) FI935309A (ko)
HU (1) HUT65884A (ko)
IL (1) IL107816A0 (ko)
MX (1) MX9306625A (ko)
NO (1) NO934334L (ko)
NZ (1) NZ248812A (ko)
SK (1) SK142693A3 (ko)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
GB9619758D0 (en) * 1996-09-23 1996-11-06 Nycomed Imaging As Method
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US5980863A (en) 1998-11-02 1999-11-09 Eagle Vision Pharmaceutical Corporation Manganese compositions and methods for MRI
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
ID29852A (id) * 1998-11-02 2001-10-18 Elan Corp Plc Cs Komposisi pelepasan modifikasi multi partikulasi
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US7459283B2 (en) * 2002-02-04 2008-12-02 Elan Pharma International Limited Nanoparticulate compositions having lysozyme as a surface stabilizer
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
EP1401401B1 (en) * 2001-06-22 2005-03-30 Marie Lindner Method for high through put screening using a small scale mill or microfluidics
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JP4464129B2 (ja) * 2001-09-19 2010-05-19 エラン ファーマ インターナショナル，リミティド ナノ粒子インスリン製剤
ATE371442T1 (de) * 2001-10-12 2007-09-15 Elan Pharma Int Ltd Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US20030152519A1 (en) * 2001-11-07 2003-08-14 Reinhard Koenig Methods for vascular imaging using nanoparticulate contrast agents
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003082213A2 (en) * 2002-03-28 2003-10-09 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
DK1494649T3 (da) 2002-04-12 2012-04-10 Alkermes Pharma Ireland Ltd Nanopartikel-megestrolformuleringer
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
EP1503737B1 (en) * 2002-05-06 2009-01-07 Elan Pharma International Limited Nanoparticulate nystatin formulations
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
JP4878839B2 (ja) * 2002-09-11 2012-02-15 エラン ファーマ インターナショナル，リミティド ゲル安定化ナノパーティクル活性物質組成物
JP2006501936A (ja) * 2002-10-04 2006-01-19 エラン ファーマ インターナショナル，リミティド 固体ナノ粒子活性薬剤のガンマ線照射
US20040156895A1 (en) * 2002-11-12 2004-08-12 Elan Pharma International Ltd. Solid dosage forms comprising pullulan
JP4614281B2 (ja) * 2002-12-16 2011-01-19 ジーイー・ヘルスケア・アクスイェ・セルスカプ 磁気共鳴撮像方法並びに該方法に用いられる化合物
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
DE602004018150D1 (de) * 2003-08-08 2009-01-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
US7879360B2 (en) * 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
US7419654B2 (en) * 2004-10-08 2008-09-02 Mrinal K. Dewanjee Charge neutral complexes of paramagnetic metals as intracellular magnetic resonance imaging contrast agents
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
WO2006066063A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
MX2007008212A (es) * 2005-01-06 2007-08-16 Elan Pharma Int Ltd Formulaciones de candesartan en nanoparticulas.
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
CA2601179A1 (en) * 2005-03-16 2006-09-21 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
KR20070121759A (ko) * 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 비스포스포네이트 조성물
BRPI0609700A2 (pt) * 2005-03-23 2010-04-20 Elan Pharma Int Ltd formulações de corticosteróide nanoparticulado e antihistamina
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
CA2603084A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
WO2007086914A2 (en) * 2005-05-10 2007-08-02 Elan Pharma International, Limited Nanoparticulate clopidogrel formulations
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20060292214A1 (en) * 2005-06-03 2006-12-28 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
JP2008542397A (ja) * 2005-06-03 2008-11-27 エラン ファーマ インターナショナル リミテッド ナノ粒子メシル酸イマチニブ製剤
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
JP2009517485A (ja) 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド セフジトレンを含むナノ粒子状および制御放出組成物
US20070059371A1 (en) * 2005-06-09 2007-03-15 Elan Pharma International, Limited Nanoparticulate ebastine formulations
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
KR20090015994A (ko) * 2006-05-30 2009-02-12 엘란 파마 인터내셔널 리미티드 나노입자형 포사코나졸 제제
TW200820991A (en) * 2006-07-10 2008-05-16 Elan Pharma Int Ltd Nanoparticulate sorafenib formulations
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
JP2011520779A (ja) * 2008-03-21 2011-07-21 エラン・ファルマ・インターナショナル・リミテッド イマチニブの部位特異的送達のための組成物および使用の方法
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
AU2010254180B2 (en) 2009-05-27 2015-08-27 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
WO2016178876A2 (en) 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EA201790844A1 (ru) * 2017-05-15 2018-11-30 Деркач, Олег Вадимович Контрастное средство на основе аморфных или аморфно-кристаллических наночастиц оксидов или гидроксидов марганца для мрт исследований мозга

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720386A (en) * 1976-11-24 1988-01-19 Mccollester Duncan L Vaccine and method for immunotherapy of neoplastic disease
GB2012162B (en) * 1977-11-24 1982-08-11 Mccollester Duncan Lee Composition for use in the immunotherapy of neoplastic disease
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
CA1182748A (en) * 1980-11-21 1985-02-19 Gerard Marx Method for synthesizing procoagulant factor viii activity
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
JPS60221043A (ja) * 1984-04-18 1985-11-05 Toyo Jozo Co Ltd 飼料用糖ブロツクおよびそれを用いる飼育法
DE3577185D1 (de) * 1984-11-01 1990-05-23 Nycomed As Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
IT1213029B (it) * 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
FR2596399B1 (fr) * 1986-03-28 1988-09-02 Univ Rennes Nanoparticules a base de polymere ou copolymere methacrylique, procede de preparation, et application comme vecteur de medicament
US4889931A (en) * 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
US5077037A (en) * 1990-08-03 1991-12-31 Mallinckrodt Medical, Inc. Novel compositions for magnetic resonance imaging
US5143716A (en) * 1991-02-01 1992-09-01 Unger Evan C Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region
US5344640A (en) * 1991-10-22 1994-09-06 Mallinckrodt Medical, Inc. Preparation of apatite particles for medical diagnostic imaging

Also Published As

Publication number Publication date
JPH06199703A (ja) 1994-07-19
EP0605908A2 (en) 1994-07-13
NO934334D0 (no) 1993-11-30
CN1102348A (zh) 1995-05-10
FI935309A (fi) 1994-06-18
IL107816A0 (en) 1994-04-12
HUT65884A (en) 1994-07-28
EP0605908A3 (en) 1994-08-17
NZ248812A (en) 1995-11-27
CZ265093A3 (en) 1994-08-17
FI935309A0 (fi) 1993-11-29
SK142693A3 (en) 1994-10-05
HU9303489D0 (en) 1994-04-28
CA2107695A1 (en) 1994-06-18
MX9306625A (es) 1994-06-30
NO934334L (no) 1994-06-20
US5401492A (en) 1995-03-28
AU4885093A (en) 1994-06-30

Similar Documents

Publication Publication Date Title
KR940013538A (ko) 자기공명 조영 강화제인 수불용성 망간입자
IL103722A (en) Emulsions containing alkylglycerophosphoryl choline surfactants
JPS5326806A (en) Low irritating detergent composition
DE69105106D1 (de) Im wasser schnell suspendierbare pharmazeutische zusammensetzung.
DE69519667D1 (de) Verfahren zur stabilisierung von duocarmycinderivaten
FI961169A0 (fi) Kiteinen vedetön mykofenolaattimofetiili ja sen intravenoosivalmiste
CA2383600A1 (en) Method for determining viability of a myocardial segment
BR9102579A (pt) Formulacao radiofarmaceutica,metodo de administracao e processo para preparacao de uma formulacao radiofarmaceutica
CA2019704A1 (en) N,n-disubstituted phthalamic acids and their ammonium salts, and their uses thereof as surfactants, emulsifiers, and conditioning agents in shampoos
DE2239936C2 (de) Verfahren zur quantitativen Bestimmung von Peptidase-Enzymkonzentrationen in Homogenaten unter Verwendung von 4-Methoxy-2-naphthylamiden
White et al. The effect of chelating agents on iron mobilization in Chang cell cultures
DE3870078D1 (de) Verfahren zur herstellung von aldehyden.
DK0769951T3 (da) Langtidsvirkende oxytetracyclinpræparat
Levillain et al. Localization of urea and ornithine production along mouse and rabbit nephrons: functional significance
CA2016470A1 (en) Pharmaceutical preparation and method of treatment for liver dysfunction
GB1356873A (en) Fungicidal compositions and their use
JPS57102820A (en) Agent for radiodiagnosis
ATE96286T1 (de) Verfahren zur entfernung von cholesterin aus eigelb.
ES8106147A1 (es) Procedimiento para preparar un 1,2,4-triazol-3-tiol
SU1628075A1 (ru) Способ моделировани токсической гепатопатии
JPH0742217B2 (ja) 染毛剤組成物
Miyake On the mechanism of adrenaline potentiating action of cocaine
JPS5596456A (en) Diagnostic agent labelled with technetium-99m which moves in cystic or hepatic duct
KR850001180A (ko) 아릴옥시벤조산 유도체의 제조방법
Bartel Sulfonamide sensitivity of Brine shrimp, Artemia salina, Nauplii: an approach to anion transport mechanism

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid